1. Home
  2. IMRN vs LAES Comparison

IMRN vs LAES Comparison

Compare IMRN & LAES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.89

Market Cap

7.7M

Sector

Health Care

ML Signal

N/A

Logo SEALSQ Corp

LAES

SEALSQ Corp

N/A

Current Price

$1.15

Market Cap

368.9M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
IMRN
LAES
Founded
1994
2022
Country
Australia
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
368.9M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
IMRN
LAES
Price
$0.89
$1.15
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $5.88
AVG Volume (30 Days)
13.4K
★ 3.7M
Earning Date
08-28-2026
09-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.00
$59.43
Revenue Next Year
N/A
$41.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$1.01
52 Week High
$1.99
$5.48

Technical Indicators

Market Signals
Indicator
IMRN
LAES
Relative Strength Index (RSI) 37.58 31.59
Support Level $0.74 N/A
Resistance Level $0.89 $2.56
Average True Range (ATR) 0.07 0.12
MACD 0.01 0.00
Stochastic Oscillator 36.84 20.34

Price Performance

Historical Comparison
IMRN
LAES

About IMRN Immuron Limited

Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

Share on Social Networks: